• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Sectors Health

NAFDAC recalls Cardura XL hypertension drug over impurity concerns 

Rosalia Ozibo by Rosalia Ozibo
September 24, 2024
in Health, Sectors
NAFDAC recalls Cardura XL hypertension drug over impurity concerns 
Share on FacebookShare on TwitterShare on Linkedin

National Agency for Food and Drugs Administration and Control (NAFDAC) has issued an urgent recall of two specific batches of hypertension drug, Cardura XL (Doxazosin), manufactured by the American pharmaceutical company, Viatris Inc.

The affected lots, identified by the batch numbers 81470418163765 and 81470408163764, are being recalled due failure of critical tests for impurity levels and degradation, potentially affecting patient safety.

Cardura XL contains doxazosin mesylate and is commonly used to treat high blood pressure and help men with an enlarged prostate urinate better.

MoreStories

Nigeria SEC

SEC sets January 31 deadline for 2026 CMO registration renewal 

December 21, 2025
Federal Competition and Consumer Protection Commission (FCCPC) Logo

FCCPC warns inter-city transporters against arbitrary yuletide fare hikes

December 21, 2025

NAFDAC’s directive calls for immediate caution from importers, distributors, and retailers. They are advised to avoid the sale and distribution of the affected drug lots.

Potential risks 

The use of poor-quality drugs, such as those that do not meet impurity and degradation standards, poses significant health risks. These risks range from ineffective treatment to more severe consequences, including allergic reactions, anxiety, harm to the patient, or in extreme cases, death.

NAFDAC has urged anyone in possession of the affected Cardura XL lots to immediately halt the use or sale of the drug. They are instructed to return the products to the nearest NAFDAC office.

Consumers who have used the drug and experienced any adverse effects are strongly encouraged to seek medical attention.

Substandard medicines 

NAFDAC has opened multiple channels for reporting substandard medicines.

Healthcare professionals and consumers can report suspicious or falsified drugs by contacting NAFDAC through its toll-free number (0800-162-3322), via email (sf.alert@nafdac.gov.ng), or by using the Med-safety app, available for download on both Android and iOS platforms.

What you should know 

The National Agency for Food and Drug Administration and Control (NAFDAC) had also recalled Dove Beauty Cream Bar Soap (100g) with batch number 81832M 08, produced in Germany, due to the detection of a harmful chemical impurity.

The soap contains Butylphenyl Methylpropional (BMHCA), commonly known as Lilial, which is banned in cosmetic products due to its potential health risks, particularly reproductive harm and skin sensitization. This chemical is often found in perfumes and has been linked to adverse effects on unborn children.

NAFDAC emphasized that the inclusion of BMHCA in the soap violates the Cosmetic Products Regulation, leading to the recall of this batch. Additionally, several other Dove products, such as Derma Spa Goodness and Men Care, have also been recalled or banned in various countries for similar reasons. The agency has reiterated the prohibition of soap importation into Nigeria.


Follow us for Breaking News and Market Intelligence.
Tags: Cardura XL hypertension drugNAFDAC
Rosalia Ozibo

Rosalia Ozibo

Rosalia is a versatile journalist with a focus on technology and education. She has a talent for turning complex ideas into engaging stories, exploring how innovation and learning shape the future of people, business, and society. From tracking shifts in digital transformation and emerging tech to writing about developments in education policy and practice, her work bridges insight and accessibility. Known for sharp analysis and compelling storytelling, she continues to provide readers with perspectives that connect knowledge, opportunity, and the evolving world of work.

Next Post
Nnamdi Kanu, Supreme Court

Nigerian Judge withdraws from FG's 'treason case' against Nnamdi Kanu, explains why 

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast
uba
tajbank

access bank
nairametrics
first bank






DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2025 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2025 Nairametrics